Literature DB >> 17683503

Intraductal chilled saline perfusion to prevent bile duct injury during percutaneous radiofrequency ablation for hepatocellular carcinoma.

Takaya Ohnishi1, Ichiro Yasuda, Youichi Nishigaki, Hideki Hayashi, Kentaro Otsuji, Tsuyoshi Mukai, Masamichi Enya, Salem Omar, Nib Soehendra, Eiichi Tomita, Hisataka Moriwaki.   

Abstract

BACKGROUND AND AIM: Radiofrequency ablation (RFA) is a promising, minimally invasive treatment for hepatocellular carcinoma (HCC). However, thermal injury sometimes occurs in the bile duct, potentially leading to a critical situation. The aim of the present study was to investigate whether bile duct injury is reduced by an intraductal chilled saline perfusion (ICSP) through a nasobiliary tube during RFA for HCC. PATIENTS AND METHODS: The baseline incidence of bile duct injury at Gifu Municipal Hospital was 3.1% (13 patients) in 424 patients with HCC treated by percutaneous RFA. In all patients, the tumor was within 5 mm of the central bile duct on CT images. The incidence of bile duct injury was 46% among the 28 selected patients whose tumor was close to the central bile duct. To prevent complications in such high-risk patients, we placed a nasobiliary tube endoscopically before RFA, and performed ICSP during RFA. Forty consecutive patients with tumors close to the central bile duct were enrolled in this study.
RESULTS: Of the 40 enrolled patients, only one had biliary injury, whereas the remaining 39 patients were able to avoid it. The incidence of biliary injury was significantly reduced in the ICSP group (1/40, 2.5%) compared to that in the control group (13/28, 46%) (P < 0.0001). Moreover, the liver function 6 months after RFA was also better preserved in the ICSP group according to Child-Pugh grading, thus resulting in a better clinical outcome.
CONCLUSIONS: ICSP through a nasobiliary tube is a potential intervention method to prevent biliary injury by percutaneous RFA.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17683503     DOI: 10.1111/j.1440-1746.2007.05091.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  15 in total

1.  A case of hepatocellular carcinoma treated by radiofrequency ablation confirming the adjacent major bile duct under hybrid contrast mode through a biliary drainage catheter.

Authors:  Yusuke Imai; Masashi Hirooka; Hironori Ochi; Yohei Koizumi; Yoshinori Ohno; Takao Watanabe; Yoshio Tokumoto; Teru Kumagi; Masanori Abe; Yoichi Hiasa
Journal:  Clin J Gastroenterol       Date:  2015-08-29

Review 2.  Complications of radiofrequency ablation of hepatic tumors: Frequency and risk factors.

Authors:  Alexandre Zanchenko Fonseca; Stephanie Santin; Luiz Guilherme Lisboa Gomes; Jaques Waisberg; Marcelo Augusto Fontenelle Ribeiro
Journal:  World J Hepatol       Date:  2014-03-27

3.  Risk Factors for Bile Duct Injury After Percutaneous Thermal Ablation of Malignant Liver Tumors: A Retrospective Case-Control Study.

Authors:  Man-Xia Lin; Jie-Yi Ye; Wen-Shuo Tian; Ming Xu; Bo-Wen Zhuang; Ming-De Lu; Xiao-Yan Xie; Ming Kuang
Journal:  Dig Dis Sci       Date:  2017-02-15       Impact factor: 3.199

Review 4.  Noninvasive Imaging Prior to Biliary Interventions.

Authors:  Roberta Catania; Anil K Dasyam; Frank H Miller; Amir A Borhani
Journal:  Semin Intervent Radiol       Date:  2021-08-10       Impact factor: 1.780

Review 5.  Radiofrequency ablation of liver tumors.

Authors:  Shaunagh McDermott; Debra A Gervais
Journal:  Semin Intervent Radiol       Date:  2013-03       Impact factor: 1.513

6.  Characterization of the biliary tract by virtual ultrasonography constructed by gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging.

Authors:  Yohei Koizumi; Masashi Hirooka; Hironori Ochi; Yoshio Tokumoto; Megumi Takechi; Atsushi Hiraoka; Yoshio Ikeda; Teru Kumagi; Bunzo Matsuura; Masanori Abe; Yoichi Hiasa
Journal:  J Med Ultrason (2001)       Date:  2014-12-18       Impact factor: 1.314

7.  Major complications after radiofrequency ablation for liver tumors: analysis of 255 patients.

Authors:  Wen-Tao Kong; Wei-Wei Zhang; Yu-Dong Qiu; Tie Zhou; Jun-Lan Qiu; Wei Zhang; Yi-Tao Ding
Journal:  World J Gastroenterol       Date:  2009-06-07       Impact factor: 5.742

8.  Impact of Radiofrequency Ablation-Induced Glisson's Capsule-Associated Complications in Patients with Hepatocellular Carcinoma.

Authors:  Toru Wakamatsu; Sadahisa Ogasawara; Tetsuhiro Chiba; Masayuki Yokoyama; Masanori Inoue; Naoya Kanogawa; Tomoko Saito; Eiichiro Suzuki; Yoshihiko Ooka; Akinobu Tawada; Osamu Yokosuka
Journal:  PLoS One       Date:  2017-01-18       Impact factor: 3.240

Review 9.  Challenges Facing Percutaneous Ablation in the Treatment of Hepatocellular Carcinoma: Extension of Ablation Criteria.

Authors:  Yanzhao Zhou; Yi Yang; Bingyan Zhou; Zhengzheng Wang; Ruili Zhu; Xun Chen; Jingzhong Ouyang; Qingjun Li; Jinxue Zhou
Journal:  J Hepatocell Carcinoma       Date:  2021-06-21

10.  Ultrasound-guided percutaneous microwave ablation assisted by three-dimensional visualization operative treatment planning system and percutaneous transhepatic cholangial drainage with intraductal chilled saline perfusion for larger hepatic hilum hepatocellular (D ≥ 3 cm): preliminary results.

Authors:  Xin Li; Jie Yu; Ping Liang; Xiaoling Yu; Zhigang Cheng; Zhiyu Han; Shaobo Duan; Jiasheng Zheng
Journal:  Oncotarget       Date:  2017-07-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.